Does the cost of IVF in Thailand increase every year? In-depth analysis of real cost trends and influencing factors
Opening: Real consultation scenario
A client who consulted me in 2023 contacted me again last week, saying that the budget was 120,000-140,000 RMB back then, but the quote for the same plan has now reached 150,000-170,000 RMB. She asked: Does the cost of IVF in Thailand increase every year? This question cannot actually be answered with a simple "yes" or "no." As a consultant with many years of experience, I break down this issue based on the cost structure, driving factors of change, and actual market conditions.
Module A: Direct answer
Direct answer: Overall costs are rising, but there is structural differentiation
From 2020 to 2024, the total cost of a standard third-generation IVF cycle (including ovarian stimulation, egg retrieval, embryo culture, PGT testing, and one frozen embryo transfer) has increased from approximately 120,000-150,000 RMB to 150,000-180,000 RMB, an increase of about 20-30%. However, the magnitude of change varies greatly between different items and hospitals. Some costs are indeed rising, while others are actually decreasing, so it cannot be generalized.
Core conclusion: The total cost of IVF in Thailand is on an upward trend, with an average annual increase of about 5-8%, but this is mainly due to medical technology upgrades and exchange rate changes, not simply "price increases." At the same time, costs for some examination items and services have actually decreased due to market competition.
Module B: Why this question arises
Four core driving factors of cost changes
1. Exchange rate fluctuations: The most direct influencing factor
IVF costs in Thailand are quoted in Thai Baht, while domestic users pay in RMB. In 2020, 1 Thai Baht ≈ 0.22 RMB, and by 2024, 1 Thai Baht ≈ 0.20-0.21 RMB. The Thai Baht has appreciated against the RMB by about 5-10% overall. For the same medical package costing 150,000 Thai Baht, it was about 33,000 RMB in 2020, and now it is about 31,000-32,000 RMB. However, hospitals often adjust their RMB quotes simultaneously, making the actual perceived increase more pronounced.
2. Medical inflation and rising labor costs
The annual inflation rate in Thailand's medical industry is about 3-5%. Labor costs, equipment maintenance, and laboratory consumables at fertility centers are all rising. This is especially true for hardware investments in the embryology lab—air purification systems, incubators, micromanipulation equipment, etc.—which require continuous investment. These costs are distributed across each cycle.
3. Technology upgrades: Iteration of PGT and embryo culture protocols
In 2020, many centers still primarily offered second-generation IVF, with a low proportion of third-generation IVF (PGT). Now, PGT-A has become almost standard, and some centers also offer PGT-SR/PGT-M testing. The popularization of PGT technology has increased the testing cost per cycle by 20,000-40,000 RMB. At the same time, embryo culture protocols have evolved from early blastocyst culture to time-lapse culture with AI-assisted selection, increasing technical costs.
4. Medication costs: The interplay between imported and domestic drugs
Ovarian stimulation medications constitute a significant part of the cost. The prices of imported drugs (such as Gonal-f and Puregon) are relatively stable, but some drugs have experienced periodic increases due to supply chain fluctuations. Domestic alternatives (such as Lishenbao and urinary gonadotropins) are cheaper, and their usage ratio is increasing. The proportion of medication costs in the total cost has decreased from 30-35% to 25-30%, mainly due to the greater diversity of medication options.
Module K: Factors influencing costs
Trends in different cost items
| Cost Item | 2020 Reference Range (RMB) | 2024 Reference Range (RMB) | Trend |
|---|---|---|---|
| Ovarian stimulation medications | 25,000 - 40,000 | 28,000 - 45,000 | ↑ Slight increase, domestic alternatives offer potential for decrease |
| Egg retrieval surgery + Embryo culture | 35,000 - 50,000 | 40,000 - 55,000 | ↑ Stable with a slight increase |
| PGT testing (single) | 20,000 - 30,000 | 25,000 - 40,000 | ↑ Increase driven by technology upgrades |
| Frozen embryo transfer | 15,000 - 25,000 | 18,000 - 30,000 | ↑ Slight increase |
| Embryo cryopreservation storage (annual fee) | 3,000 - 5,000 | 4,000 - 6,000 | ↑ Routine adjustment |
| Pre-cycle examinations (both partners) | 8,000 - 12,000 | 7,000 - 11,000 | ↓ Some examination costs decreased |
| Translation and coordination services | 10,000 - 15,000 | 8,000 - 15,000 | → Sufficient competition, prices stabilizing |
From the table above, it can be seen that costs for core medical items have generally risen, but pre-cycle examination and service costs have stabilized or even slightly decreased due to market competition. The increase in total cost mainly stems from technology upgrades and medication costs, rather than simple "price increases."
Module G: Details most easily overlooked
Five cost details most easily overlooked
- Individual variation in ovarian stimulation medication dosage: Age, ovarian reserve, BMI, etc., all affect medication dosage. Women with low AMH and high FSH may require larger doses, potentially increasing medication costs by 30-50%. Many people only see the basic package price without accounting for individual differences.
- Embryo cryopreservation renewal fee: The first year's freezing fee is usually included in the package, but subsequent years require renewal. If multiple embryos need long-term storage, this cost is easily overlooked.
- PGT testing charged per embryo: Most centers use a "base fee + per embryo charge." If a large number of blastocysts are cultured, the testing cost will increase significantly. Conversely, if there are few blastocysts, the testing cost may be lower than expected.
- Number of transfer cycles: One egg retrieval plus one transfer is the basic cost. If multiple transfers are needed, each transfer (including endometrial preparation, transfer procedure, and luteal support) costs between 18,000 and 30,000 RMB. The total cost increases with the number of transfers.
- Costs related to complications: Although the incidence is low, complications such as OHSS (Ovarian Hyperstimulation Syndrome), infection, and bleeding require additional treatment, and these costs are not included in the standard package.
Module H: Common pitfalls
Three most common pitfalls
"Hidden gaps" in low-price packages
Some institutions attract clients with low-price packages of 90,000-110,000 RMB, but a closer look reveals: PGT testing is not included, embryo freezing fees are not included, the number of transfers is limited to one, and medication dosage has an upper limit. In practice, the total cost often ends up being similar to or even higher than standard quotes. When choosing a package, be sure to confirm item by item "what is included, what is not included, and how overages are charged."
"Vague descriptions" of what is included
Some contracts state "includes ovarian stimulation medications" but do not specify the type of medication or dosage limit. The cost difference between imported and domestic drugs is significant. If the doctor prescribes imported drugs beyond the package scope, you will need to pay the difference. It is recommended to clarify the medication list and dosage limits before signing the contract.
"Hidden impact" of exchange rate fluctuations
Some institutions quote in Thai Baht, and payment in RMB is settled at the real-time exchange rate. If the Thai Baht appreciates, the actual RMB amount paid will increase. Other institutions price in RMB but adjust prices periodically. Regardless of the method, it is important to understand who bears the exchange rate risk.
Module Q: Frequently asked questions
Frequently asked questions
Q: Why is IVF in Thailand more expensive than in China?
Third-generation IVF technology is more widespread in Thailand. The application rate of technologies like PGT testing, time-lapse embryo culture, and AI-assisted selection is higher than in most centers in China. Additionally, there are differences in the medical environment, service experience, and medication options. The cost difference mainly stems from the level of technology and service system, not simply "higher pricing."
Q: Will the cost decrease?
In the short term, a significant drop in total cost is unlikely. Exchange rates, medical inflation, and technology upgrades are all pushing costs upward. However, some items (such as examination fees and basic medications) may decrease due to competition and domestic alternatives. In the medium term, the cost structure will likely become more optimized, but the total cost is expected to remain stable or increase slightly.
Q: Which hospital offers the best value for money?
The cost differences among mainstream fertility centers in Thailand (such as Jetanin, BNH, Phyathai 2, Siam Fertility Center, etc.) are not significant. The main differences lie in technical specialties and service models. When choosing, it is recommended to focus on: the type of PGT technology, embryo culture protocols, laboratory standards, and whether personalized medication plans are offered. Value for money is not just about price; success rates and suitability are also crucial.
Q: What is included in the cost? What is not included?
Standard packages usually include: ovarian stimulation medications (with an upper limit), egg retrieval surgery, embryo culture, PGT testing (basic quantity), one frozen embryo transfer, and embryo cryopreservation (first year). They typically do not include: pre-cycle examinations, medication overages, additional PGT testing, multiple transfers, complication management, embryo cryopreservation renewal fees, and translation services (some may include).
Module R: Practitioner's observation
Practitioner's observation: Three trends in cost changes
- Cost transparency is improving: In 2020, many institutions only provided a total price on their quotes without a breakdown. Now, more and more centers offer detailed cost lists, itemizing what is included and what is not. This is a positive development for users.
- Market competition drives service upgrades: The number of fertility centers in Thailand is increasing, intensifying competition. To attract clients, many institutions are improving their services—remote consultations, case management, psychological support, etc. The cost of these services is partially reflected in the fees, but overall value for money is improving.
- Personalized plans reduce unnecessary expenses: In the past, it was a "one-size-fits-all" approach. Now, more centers develop personalized plans based on the patient's age, ovarian function, and medical history. A suitable plan can not only improve efficiency but also avoid unnecessary costs.
From a practitioner's perspective, the cost issue is essentially a value issue. The cost of one cycle may seem high, but compared to the technical limitations and cumulative costs of multiple attempts at some centers in China, the maturity of technology and processes in Thailand IVF remains a reasonable choice for many families.
Ending: Risk reminder
Risk reminder: Cost is just one dimension in decision-making. When choosing IVF in Thailand, it is recommended to focus on "whether the plan is suitable for you" and "whether the center's laboratory standards are reliable." Low-price packages are often accompanied by reduced services or hidden fees. Be sure to obtain a complete cost breakdown before signing the contract and confirm the charging standards and limits for each item. Do not be swayed by marketing phrases like "all-inclusive price" or "guaranteed success." Assisted reproduction has no 100% guarantee. Only by rationally viewing the relationship between cost and outcome can you make a decision that is best for you.
